SpecGx































you are drinking some koolaide friend. What smear campaign?!? What has been reported that is untrue or grossly inaccurate. Short sellers and 60 minutes, CNN are just telling the other half to the story that management try’s to hide. If this “smear campaign” was so off base management would be going after these outlets legally. They aren’t because most of what is reported isn’t that off base. I feel bad for people that can’t look at both sides. Find the truth in the middle and realize that while Acthar has the potential to be a life saving therapy for many many patients. It’s owned by terrible stewards of the product who have a hopelessly flawed and unsustainable business model and are more focused on greed than in truly helping patients. Few are saying that the reps don’t believe in the product or the product have no merits because the do. Rather just that MNK needs new leadership and direction for Acthar
 














































































Q2 results will be a good quarter, 4/5 TAs exceeded goal however referrals were very soft to close Q2 and plummeted post CNN and have not recovered. Combine that to lost Optum patients as PAs expire and Q3 isn’t going to look pretty and Q4 will be worse. Don’t mistake Q2 results with the overall health for Acthar. Overall health for Acthar is not good